A Novel Model for the Screening of Varices in Patients with Compensated Cirrhosis: an International Multicenter Study
Chuan Liu,Jia Li,Qing-Lei Zeng,Hong You,Dong Ji,YJ Wong,Ye Gu,Guo Zhang,Lili Zhao,Yang Bo,Qing Xie,Fengmei Wang,Shuang Li,Guofeng Chen,Yan Wang,Shengjuan Hu,Xiaoli Wu,Jinlun Bao,Yongning Xin,Doudou Hu,Zicheng Jiang,Xiaoling Chi,Yong Zhang,Chunwen Pu,Ming Lu,Li,Deqiang Ma,Qibin He,Mingxin Zhang,Huan Liu,Chao Liu,Li Yang,Chaohui He,Shanhong Tang,Chunyan Wang,Wenjuan Wang,Peng Hua,Liting Zhang,Minghua Zheng,Dengxiang Liu,Pingcuo Zhaxi,Xiaosong Yan,Bianba Yangzhen,Fuji Mao,Chun Song,Jiafu Ao,Taiyun Zhao,Youfang Gao,Hao Hu,Jun Wu,Yan Liu,Tinghong Li,Huiling Xiang,Musong Li,Zhujun Cao,Hailong Qi,Shengqiang Zou,Guohong Ge,Jiangbo Shao,Bingqiong Wang,Ping Li,Tao Han,Lei Li,Ming-Hui Li,Wen Xie,Wei Jiang,Mingyi Xu,Bo Feng,Jilin Cheng,Xiaozhong Wang,Hai Li,Hongxin Piao,Jiansong Ji,Chu xiao Shao,Tong Dang,Yi Zhou,Juan Tang,Guochang He,Li Dong,Jun Li,Xiqiao Zhou,Guoxin Zhang,Kok Ban Teh,Yanna Liu,Lin Zhang,Yiling Li,Liang Chen,Manoj Kumar,Ankur Jindal,Wei Qin,Zhenhuai Chen,Don C. Rockey,Jiahong Dong,Shiv Kumar Sarin,Xiaolong Qi
DOI: https://doi.org/10.2139/ssrn.4052664
2022-01-01
Abstract:Background and Aims: The Baveno VI and expanded-Baveno VI criteria has been validated as single-use screening for varices needing treatment (VNT) in patients enriched with hepatitis C virus and alcoholic-related compensated cirrhosis. Here, we aimed to develop and validate novel CHESS model for single-use screening and dynamic monitoring of VNT in patients with predominantly hepatitis B virus (HBV)-related compensated cirrhosis. Methods: A total of 3,470 patients with compensated cirrhosis from China, Singapore and India were included in the international multicenter study with six cohorts as follows: real-world cohort; multicenter validation cohort; international validation cohort; multicenter HBV cohort; dynamic monitoring longitudinal cohort; multicenter, clinical practice cohort. Primary outcomes were the rates of VNT missed and spared esophagogastroduodenoscopy (EGD).Results: In the real-world cohort (65%HBV), implementing Baveno VI criteria would have spared 30% of EGDs and missed 3·6% of VNT. Expanded-Baveno VI criteria had an unacceptable VNT missed rate of 6·2%. Using the new CHESS model (platelets>110×109/L and liver stiffness<19kPa) would have spared 46% of EGDs (p<0.001 vs. Baveno VI criteria) and missed 4·9% of VNT. In the multicenter cohort (75%HBV), international cohort (14%HBV) and HBV cohort, CHESS model would also have spared more EGDs (all p<0·001) than Baveno VI criteria. Notably, employing CHESS model in dynamic monitoring cohort would have safely spared 41% and 54% of EGDs for primary and secondary monitoring, respectively. In the prospective clinical practice cohort, 75% of EGDs were spared according to CHESS model, with a VNT rate of 36% in patients dissatisfied CHESS model who underwent EGD.Conclusion: CHESS model were superior to Baveno VI criteria and expanded-Baveno VI criteria for the screening and monitoring of varices in patients with HBV-dominated compensated cirrhosis.Funding Information: None. Declaration of Interests: None.Ethics Approval Statement: All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the Ethics Committees of all the involved centers. The committees waived the need for written informed consent from subjects in two retrospective cohorts because de-identified secondary data were analyzed. Written informed consent was obtained from all patients prior to inclusion in the prospective cohorts.